VERACYTE INC (VCYT) Stock Fundamental Analysis
USA - NASDAQ:VCYT - US92337F1075 - Common Stock
39.35 USD
-0.52 (-1.3%)
39.35 USD
0 (0%)
VCYT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. VCYT has an average financial health and profitability rating. VCYT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year VCYT was profitable.
In the past year VCYT had a positive cash flow from operations.
In the past 5 years VCYT reported 4 times negative net income.
In multiple years VCYT reported negative operating cash flow during the last 5 years.
1.2 Ratios
VCYT's Return On Assets of 2.22% is amongst the best of the industry. VCYT outperforms 89.64% of its industry peers.
The Return On Equity of VCYT (2.41%) is better than 90.77% of its industry peers.
The Return On Invested Capital of VCYT (2.93%) is better than 90.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROIC | 2.93% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VCYT's Profit Margin of 6.12% is amongst the best of the industry. VCYT outperforms 91.15% of its industry peers.
With an excellent Operating Margin value of 9.70%, VCYT belongs to the best of the industry, outperforming 91.71% of the companies in the same industry.
VCYT has a Gross Margin of 68.53%. This is amongst the best in the industry. VCYT outperforms 81.17% of its industry peers.
VCYT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VCYT is destroying value.
Compared to 1 year ago, VCYT has more shares outstanding
Compared to 5 years ago, VCYT has more shares outstanding
There is no outstanding debt for VCYT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VCYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC0.33
WACC8.75%
2.3 Liquidity
VCYT has a Current Ratio of 6.23. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
VCYT has a Current ratio of 6.23. This is in the better half of the industry: VCYT outperforms 66.29% of its industry peers.
VCYT has a Quick Ratio of 5.94. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VCYT (5.94) is better than 63.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 353.33% over the past year.
VCYT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.41%.
VCYT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.93% yearly.
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
3.2 Future
VCYT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.66% yearly.
The Revenue is expected to grow by 9.91% on average over the next years. This is quite good.
EPS Next Y33.17%
EPS Next 2Y67.82%
EPS Next 3Y57.77%
EPS Next 5Y50.66%
Revenue Next Year12.89%
Revenue Next 2Y11.38%
Revenue Next 3Y10.9%
Revenue Next 5Y9.91%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 103.55 indicates a quite expensive valuation of VCYT.
Based on the Price/Earnings ratio, VCYT is valued cheaper than 89.64% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.89. VCYT is valued rather expensively when compared to this.
VCYT is valuated quite expensively with a Price/Forward Earnings ratio of 46.57.
Based on the Price/Forward Earnings ratio, VCYT is valued cheaper than 90.02% of the companies in the same industry.
VCYT's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 34.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 103.55 | ||
| Fwd PE | 46.57 |
4.2 Price Multiples
91.34% of the companies in the same industry are more expensive than VCYT, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 93.41% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.52 | ||
| EV/EBITDA | 38.63 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VCYT does not grow enough to justify the current Price/Earnings ratio.
VCYT has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as VCYT's earnings are expected to grow with 57.77% in the coming years.
PEG (NY)3.12
PEG (5Y)N/A
EPS Next 2Y67.82%
EPS Next 3Y57.77%
5. Dividend
5.1 Amount
VCYT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
39.35
-0.52 (-1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners109.55%
Inst Owner Change0.47%
Ins Owners0.56%
Ins Owner Change-1.19%
Market Cap3.10B
Revenue(TTM)495.14M
Net Income(TTM)30.32M
Analysts83.33
Price Target42.94 (9.12%)
Short Float %8.59%
Short Ratio7.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-110.32%
Max EPS beat(2)79.03%
EPS beat(4)2
Avg EPS beat(4)-1.91%
Min EPS beat(4)-110.32%
Max EPS beat(4)79.03%
EPS beat(8)5
Avg EPS beat(8)108.97%
EPS beat(12)8
Avg EPS beat(12)67.3%
EPS beat(16)12
Avg EPS beat(16)58.01%
Revenue beat(2)2
Avg Revenue beat(2)4.54%
Min Revenue beat(2)3.31%
Max Revenue beat(2)5.76%
Revenue beat(4)3
Avg Revenue beat(4)2.42%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)5.76%
Revenue beat(8)7
Avg Revenue beat(8)4.03%
Revenue beat(12)11
Avg Revenue beat(12)4.6%
Revenue beat(16)15
Avg Revenue beat(16)5.32%
PT rev (1m)2.13%
PT rev (3m)1.69%
EPS NQ rev (1m)7.73%
EPS NQ rev (3m)1.1%
EPS NY rev (1m)5.86%
EPS NY rev (3m)-22.95%
Revenue NQ rev (1m)0.47%
Revenue NQ rev (3m)0.71%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)1.74%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 103.55 | ||
| Fwd PE | 46.57 | ||
| P/S | 6.25 | ||
| P/FCF | 31.52 | ||
| P/OCF | 28.6 | ||
| P/B | 2.46 | ||
| P/tB | 7.78 | ||
| EV/EBITDA | 38.63 |
EPS(TTM)0.38
EY0.97%
EPS(NY)0.84
Fwd EY2.15%
FCF(TTM)1.25
FCFY3.17%
OCF(TTM)1.38
OCFY3.5%
SpS6.29
BVpS15.99
TBVpS5.06
PEG (NY)3.12
PEG (5Y)N/A
Graham Number11.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROCE | 3.71% | ||
| ROIC | 2.93% | ||
| ROICexc | 4.08% | ||
| ROICexgc | 54.52% | ||
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% | ||
| FCFM | 19.83% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
F-Score8
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 44.87% | ||
| Cap/Sales | 2.03% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.79% | ||
| Profit Quality | 323.94% | ||
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 | ||
| Altman-Z | N/A |
F-Score8
WACC8.75%
ROIC/WACC0.33
Cap/Depr(3y)39.24%
Cap/Depr(5y)36.19%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y33.17%
EPS Next 2Y67.82%
EPS Next 3Y57.77%
EPS Next 5Y50.66%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
Revenue Next Year12.89%
Revenue Next 2Y11.38%
Revenue Next 3Y10.9%
Revenue Next 5Y9.91%
EBIT growth 1Y426.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year275.46%
EBIT Next 3Y68.01%
EBIT Next 5Y45.61%
FCF growth 1Y237.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y181.75%
OCF growth 3YN/A
OCF growth 5YN/A
VERACYTE INC / VCYT FAQ
What is the fundamental rating for VCYT stock?
ChartMill assigns a fundamental rating of 5 / 10 to VCYT.
What is the valuation status for VCYT stock?
ChartMill assigns a valuation rating of 5 / 10 to VERACYTE INC (VCYT). This can be considered as Fairly Valued.
How profitable is VERACYTE INC (VCYT) stock?
VERACYTE INC (VCYT) has a profitability rating of 6 / 10.
How financially healthy is VERACYTE INC?
The financial health rating of VERACYTE INC (VCYT) is 6 / 10.
What is the expected EPS growth for VERACYTE INC (VCYT) stock?
The Earnings per Share (EPS) of VERACYTE INC (VCYT) is expected to grow by 33.17% in the next year.